|
Drug
type |
Polymer
type |
Patients
number |
Follow-up
(month) |
Death
(%) |
MI
(%) |
ST
(%) |
TLR
(%) |
Late loss
(mm) |
LEADERS49-52 |
Biolimus A9 |
PLA |
857 |
9 |
2.6 |
5.7 |
2.6 |
5.4 |
0.13 |
|
|
|
|
24 |
4.7 |
6.3 |
2.9 |
7.9 |
….. |
|
|
|
|
48 |
9.2 |
8.3 |
3.4 |
10.3 |
….. |
CUSTOM I59 |
Biolimus A9 |
PLA |
30 |
24 / 8* |
3.3 |
6.6 |
0 |
3.3 |
0.26 |
CUSTOM II60 |
Biolimus A9 |
PLA |
100 |
12 / 6* |
1.0 |
4.0 |
1.0 |
4.0 |
0.31 |
ISAR-TEST-353,54 |
Sirolimus |
PLA |
202 |
12 / 6-8* |
2.0 |
1.5# |
0.5 |
5.9 |
0.17 |
|
|
|
|
24 |
3.5 |
2.5# |
0.5 |
8.4 |
….. |
ISAR-TEST-455,56 |
Sirolimus |
PLA |
1299 |
12 |
4.7 |
4.3 |
1.0 |
8.8 |
….. |
|
|
|
|
36 |
9.3 |
4.6## |
1.2 |
13.9 |
….. |
NEVO RES- I57 |
Sirolimus |
PLGA |
198 |
6 |
0.5 |
2.0 |
0 |
3.6 |
0.13 |
SERIES I61 |
Sirolimus |
Mixed++ |
100 |
30 / 6* |
3.0 |
1.0 |
1.0 |
4.0 (TVR) |
0.09 |
FUTURE I62 |
Everolimus |
PLA |
27 |
12 / 6* |
3.8 |
0 |
0 |
3.8 |
0.11 |
MAHOROBA63 |
Tacrolimus |
PLGA |
47 |
6 |
0 |
4.3 |
2.1+ |
23.4 |
0.99 |
COSTAR I64 |
Paclitaxel |
PLGA |
87 |
12 |
2.3 |
8.0 |
3.4 |
5.7 |
0.55-0.90 |
COSTAR II58 |
Paclitaxel |
PLGA |
989 |
8 / 9* |
0.5 |
3.4 |
0.6 |
8.1 (TVR) |
0.64 |
EUROSTAR65 |
Paclitaxel |
PLGA |
282 |
12 / 6* |
2.1 |
3.9 |
1.1 |
3.1 |
0.28-0.40 |
EUROSTAR II66 |
Paclitaxel |
PLGA |
152 |
8 |
0 |
3.3 |
0 |
15.1 |
0.41 |
STELLIUM67 |
Paclitaxel |
PLGA |
37 |
6 |
0 |
0 |
0 |
2.7 |
0.19 |
JACTAX68 |
Paclitaxel |
PLA |
103 |
9 |
0 |
1.9 |
0 |
1.9 |
0.33 |
MI: Myocardial Infarction; ST: Definite or probable stent thrombosis defined in Academic Research Consortium; TLR: Target Lesion Revascularization; TVR: Target Vessel
Revascularization; PLA: Polylactic Acid; PLGA: Polylactide-co-glycolic Acid; ++ Mixed polymer with PLLA (Poly L-Lactic acid), PLGA (50/50 Poly DL-Lactide-co-Glycolide)
and PVP (Polyvinyl Pyrrolidone); * Clinical/angiographic follow-up; # Q wave MI only; ## Target vessel MI only; + Definite stent thrombosis only. |